Zymeworks Inc. has transitioned from a development-stage biotech to a revenue-generating company following FDA approval of zanidatamab for first-line HER2+ gastroesophageal cancer. This approval expands the patient base and triggers a $250 million milestone payment plus 10–20% tiered royalties, boosting near-term revenue potential. The company's future growth depends on successful commercial execution, label expansions, and integrating cash-flow assets like YUPELRI from its pending acquisition of Theravance. Market valuation reflects both the opportunity for increased revenues and the risks involved in this transition.
BlackRock has purchased over $3.1 billion worth of Bitcoin and Ethereum in just eight days, acquiring 22,722 BTC and 385,633 ETH. This surge in buying coincides with a strong recovery in the broader cryptocurrency market. BlackRock's crypto funds, in...
Marvell Technology reported Q2 earnings and revenue above Wall Street expectations, with data center revenue up 46% year-over-year to $2.17 billion, driven by robust AI-related bookings. Despite this, shares fell 8% in premarket trading as investors ...
Cardano's ADA price rose 1.08% to $0.2147, maintaining support above $0.2004 amid optimism from the Ouroboros Leios protocol test. This test increased Cardano's transaction capacity by 500%, with four more testing phases before a planned mainnet upgr...
Hyperliquid Strategies raised $647 million in equity during its fiscal year ending June 30, 2026, using the funds to increase its HYPE token holdings to 29.3 million tokens valued at about $1.9 billion. The company reported net income of $305.5 milli...
Bitcoin price is steadily climbing toward a key resistance level near $83,000, which could mark a shift from a bear to a bull market if surpassed. However, technical indicators like the RSI show bearish divergence, suggesting momentum may be weakenin...
